Heimdall Insights

Global Adrenomyeloneuropathy Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: July 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Adrenomyeloneuropathy Market was valued at $280 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 12.5% CAGR, to an estimated market size of $505 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

Adrenomyeloneuropathy (AMN) is the most common adult-onset phenotype of X-linked Adrenoleukodystrophy (X-ALD), a rare genetic disorder caused by mutations in the ABCD1 gene. It is characterized by the systemic accumulation of very long-chain fatty acids (VLCFAs), which leads to the progressive demyelination of the spinal cord and peripheral nerves, as well as adrenal insufficiency (Addison's disease).

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Adrenomyeloneuropathy Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Gene Therapy
  • Hormone Replacement Therapy
  • Supportive & Symptomatic Care
  • Stem Cell Transplant (HSCT)